KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)

Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this is...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Isakova, Tamara [verfasserIn] Nickolas, Thomas L. Denburg, Michelle Yarlagadda, Sri Weiner, Daniel E. Gutiérrez, Orlando M. Bansal, Vinod Rosas, Sylvia E. Nigwekar, Sagar Yee, Jerry Kramer, Holly

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2017transfer abstract

Schlagwörter:	dialysis calcium renal osteodystrophy clinical practice guideline phosphate parathyroid hormone (PTH) Chronic kidney disease–mineral and bone disorder (CKD-MBD) nephrology best practices phosphate binders mineral metabolism end-stage renal disease (ESRD) bone mineral density (BMD) evidence-based medicine

Umfang:	15

Übergeordnetes Werk:	Enthalten in: The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested - 2013, AJKD : official journal of the National Kidney Foundation, Philadelphia, Pa
Übergeordnetes Werk:	volume:70 ; year:2017 ; number:6 ; pages:737-751 ; extent:15

Links:	Volltext

DOI / URN:	10.1053/j.ajkd.2017.07.019

Katalog-ID:	ELV041125940

Internformat


LEADER	01000caa a22002652 4500
001	ELV041125940
003	DE-627
005	20230625233754.0
007	cr uuu---uuuuu
008	180725s2017 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1053/j.ajkd.2017.07.019 \|2 doi
028	5	2	\|a GBV00000000000043A.pica
035			\|a (DE-627)ELV041125940
035			\|a (ELSEVIER)S0272-6386(17)30898-3
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0		\|a 610
082	0	4	\|a 610 \|q DNB
082	0	4	\|a 610 \|q VZ
082	0	4	\|a 530 \|q VZ
084			\|a 52.56 \|2 bkl
100	1		\|a Isakova, Tamara \|e verfasserin \|4 aut
245	1	0	\|a KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
264		1	\|c 2017transfer abstract
300			\|a 15
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a nicht spezifiziert \|b z \|2 rdamedia
338			\|a nicht spezifiziert \|b zu \|2 rdacarrier
520			\|a Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment.
520			\|a Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment.
650		7	\|a dialysis \|2 Elsevier
650		7	\|a calcium \|2 Elsevier
650		7	\|a renal osteodystrophy \|2 Elsevier
650		7	\|a clinical practice guideline \|2 Elsevier
650		7	\|a phosphate \|2 Elsevier
650		7	\|a parathyroid hormone (PTH) \|2 Elsevier
650		7	\|a Chronic kidney disease–mineral and bone disorder (CKD-MBD) \|2 Elsevier
650		7	\|a nephrology best practices \|2 Elsevier
650		7	\|a phosphate binders \|2 Elsevier
650		7	\|a mineral metabolism \|2 Elsevier
650		7	\|a end-stage renal disease (ESRD) \|2 Elsevier
650		7	\|a bone mineral density (BMD) \|2 Elsevier
650		7	\|a evidence-based medicine \|2 Elsevier
700	1		\|a Nickolas, Thomas L. \|4 oth
700	1		\|a Denburg, Michelle \|4 oth
700	1		\|a Yarlagadda, Sri \|4 oth
700	1		\|a Weiner, Daniel E. \|4 oth
700	1		\|a Gutiérrez, Orlando M. \|4 oth
700	1		\|a Bansal, Vinod \|4 oth
700	1		\|a Rosas, Sylvia E. \|4 oth
700	1		\|a Nigwekar, Sagar \|4 oth
700	1		\|a Yee, Jerry \|4 oth
700	1		\|a Kramer, Holly \|4 oth
773	0	8	\|i Enthalten in \|n Elsevier Saunders \|t The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested \|d 2013 \|d AJKD : official journal of the National Kidney Foundation \|g Philadelphia, Pa \|w (DE-627)ELV011405082
773	1	8	\|g volume:70 \|g year:2017 \|g number:6 \|g pages:737-751 \|g extent:15
856	4	0	\|u https://doi.org/10.1053/j.ajkd.2017.07.019 \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
912			\|a GBV_ILN_11
912			\|a GBV_ILN_40
936	b	k	\|a 52.56 \|j Regenerative Energieformen \|j alternative Energieformen \|q VZ
951			\|a AR
952			\|d 70 \|j 2017 \|e 6 \|h 737-751 \|g 15
953			\|2 045F \|a 610

Indexfelder

author_variant	t i ti
matchkey_str	isakovatamaranickolasthomasldenburgmiche:2017----:dqucmetrote07dgciiapatcgieiepaeoteigoieautopeetoadramnocrn
hierarchy_sort_str	2017transfer abstract
bklnumber	52.56
publishDate	2017
allfields	10.1053/j.ajkd.2017.07.019 doi GBV00000000000043A.pica (DE-627)ELV041125940 (ELSEVIER)S0272-6386(17)30898-3 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Isakova, Tamara verfasserin aut KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) 2017transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment. Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment. dialysis Elsevier calcium Elsevier renal osteodystrophy Elsevier clinical practice guideline Elsevier phosphate Elsevier parathyroid hormone (PTH) Elsevier Chronic kidney disease–mineral and bone disorder (CKD-MBD) Elsevier nephrology best practices Elsevier phosphate binders Elsevier mineral metabolism Elsevier end-stage renal disease (ESRD) Elsevier bone mineral density (BMD) Elsevier evidence-based medicine Elsevier Nickolas, Thomas L. oth Denburg, Michelle oth Yarlagadda, Sri oth Weiner, Daniel E. oth Gutiérrez, Orlando M. oth Bansal, Vinod oth Rosas, Sylvia E. oth Nigwekar, Sagar oth Yee, Jerry oth Kramer, Holly oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:70 year:2017 number:6 pages:737-751 extent:15 https://doi.org/10.1053/j.ajkd.2017.07.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 70 2017 6 737-751 15 045F 610
spelling	10.1053/j.ajkd.2017.07.019 doi GBV00000000000043A.pica (DE-627)ELV041125940 (ELSEVIER)S0272-6386(17)30898-3 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Isakova, Tamara verfasserin aut KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) 2017transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment. Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment. dialysis Elsevier calcium Elsevier renal osteodystrophy Elsevier clinical practice guideline Elsevier phosphate Elsevier parathyroid hormone (PTH) Elsevier Chronic kidney disease–mineral and bone disorder (CKD-MBD) Elsevier nephrology best practices Elsevier phosphate binders Elsevier mineral metabolism Elsevier end-stage renal disease (ESRD) Elsevier bone mineral density (BMD) Elsevier evidence-based medicine Elsevier Nickolas, Thomas L. oth Denburg, Michelle oth Yarlagadda, Sri oth Weiner, Daniel E. oth Gutiérrez, Orlando M. oth Bansal, Vinod oth Rosas, Sylvia E. oth Nigwekar, Sagar oth Yee, Jerry oth Kramer, Holly oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:70 year:2017 number:6 pages:737-751 extent:15 https://doi.org/10.1053/j.ajkd.2017.07.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 70 2017 6 737-751 15 045F 610
allfields_unstemmed	10.1053/j.ajkd.2017.07.019 doi GBV00000000000043A.pica (DE-627)ELV041125940 (ELSEVIER)S0272-6386(17)30898-3 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Isakova, Tamara verfasserin aut KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) 2017transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment. Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment. dialysis Elsevier calcium Elsevier renal osteodystrophy Elsevier clinical practice guideline Elsevier phosphate Elsevier parathyroid hormone (PTH) Elsevier Chronic kidney disease–mineral and bone disorder (CKD-MBD) Elsevier nephrology best practices Elsevier phosphate binders Elsevier mineral metabolism Elsevier end-stage renal disease (ESRD) Elsevier bone mineral density (BMD) Elsevier evidence-based medicine Elsevier Nickolas, Thomas L. oth Denburg, Michelle oth Yarlagadda, Sri oth Weiner, Daniel E. oth Gutiérrez, Orlando M. oth Bansal, Vinod oth Rosas, Sylvia E. oth Nigwekar, Sagar oth Yee, Jerry oth Kramer, Holly oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:70 year:2017 number:6 pages:737-751 extent:15 https://doi.org/10.1053/j.ajkd.2017.07.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 70 2017 6 737-751 15 045F 610
allfieldsGer	10.1053/j.ajkd.2017.07.019 doi GBV00000000000043A.pica (DE-627)ELV041125940 (ELSEVIER)S0272-6386(17)30898-3 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Isakova, Tamara verfasserin aut KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) 2017transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment. Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment. dialysis Elsevier calcium Elsevier renal osteodystrophy Elsevier clinical practice guideline Elsevier phosphate Elsevier parathyroid hormone (PTH) Elsevier Chronic kidney disease–mineral and bone disorder (CKD-MBD) Elsevier nephrology best practices Elsevier phosphate binders Elsevier mineral metabolism Elsevier end-stage renal disease (ESRD) Elsevier bone mineral density (BMD) Elsevier evidence-based medicine Elsevier Nickolas, Thomas L. oth Denburg, Michelle oth Yarlagadda, Sri oth Weiner, Daniel E. oth Gutiérrez, Orlando M. oth Bansal, Vinod oth Rosas, Sylvia E. oth Nigwekar, Sagar oth Yee, Jerry oth Kramer, Holly oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:70 year:2017 number:6 pages:737-751 extent:15 https://doi.org/10.1053/j.ajkd.2017.07.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 70 2017 6 737-751 15 045F 610
allfieldsSound	10.1053/j.ajkd.2017.07.019 doi GBV00000000000043A.pica (DE-627)ELV041125940 (ELSEVIER)S0272-6386(17)30898-3 DE-627 ger DE-627 rakwb eng 610 610 DNB 610 VZ 530 VZ 52.56 bkl Isakova, Tamara verfasserin aut KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) 2017transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment. Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment. dialysis Elsevier calcium Elsevier renal osteodystrophy Elsevier clinical practice guideline Elsevier phosphate Elsevier parathyroid hormone (PTH) Elsevier Chronic kidney disease–mineral and bone disorder (CKD-MBD) Elsevier nephrology best practices Elsevier phosphate binders Elsevier mineral metabolism Elsevier end-stage renal disease (ESRD) Elsevier bone mineral density (BMD) Elsevier evidence-based medicine Elsevier Nickolas, Thomas L. oth Denburg, Michelle oth Yarlagadda, Sri oth Weiner, Daniel E. oth Gutiérrez, Orlando M. oth Bansal, Vinod oth Rosas, Sylvia E. oth Nigwekar, Sagar oth Yee, Jerry oth Kramer, Holly oth Enthalten in Elsevier Saunders The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested 2013 AJKD : official journal of the National Kidney Foundation Philadelphia, Pa (DE-627)ELV011405082 volume:70 year:2017 number:6 pages:737-751 extent:15 https://doi.org/10.1053/j.ajkd.2017.07.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 52.56 Regenerative Energieformen alternative Energieformen VZ AR 70 2017 6 737-751 15 045F 610
language	English
source	Enthalten in The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested Philadelphia, Pa volume:70 year:2017 number:6 pages:737-751 extent:15
sourceStr	Enthalten in The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested Philadelphia, Pa volume:70 year:2017 number:6 pages:737-751 extent:15
format_phy_str_mv	Article
bklname	Regenerative Energieformen alternative Energieformen
institution	findex.gbv.de
topic_facet	dialysis calcium renal osteodystrophy clinical practice guideline phosphate parathyroid hormone (PTH) Chronic kidney disease–mineral and bone disorder (CKD-MBD) nephrology best practices phosphate binders mineral metabolism end-stage renal disease (ESRD) bone mineral density (BMD) evidence-based medicine
dewey-raw	610
isfreeaccess_bool	false
container_title	The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested
authorswithroles_txt_mv	Isakova, Tamara @@aut@@ Nickolas, Thomas L. @@oth@@ Denburg, Michelle @@oth@@ Yarlagadda, Sri @@oth@@ Weiner, Daniel E. @@oth@@ Gutiérrez, Orlando M. @@oth@@ Bansal, Vinod @@oth@@ Rosas, Sylvia E. @@oth@@ Nigwekar, Sagar @@oth@@ Yee, Jerry @@oth@@ Kramer, Holly @@oth@@
publishDateDaySort_date	2017-01-01T00:00:00Z
hierarchy_top_id	ELV011405082
dewey-sort	3610
id	ELV041125940
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041125940</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625233754.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180725s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1053/j.ajkd.2017.07.019</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000043A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041125940</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0272-6386(17)30898-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">52.56</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Isakova, Tamara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">dialysis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">calcium</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">renal osteodystrophy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">clinical practice guideline</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">phosphate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">parathyroid hormone (PTH)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chronic kidney disease–mineral and bone disorder (CKD-MBD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">nephrology best practices</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">phosphate binders</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mineral metabolism</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">end-stage renal disease (ESRD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">bone mineral density (BMD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">evidence-based medicine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nickolas, Thomas L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Denburg, Michelle</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yarlagadda, Sri</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiner, Daniel E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gutiérrez, Orlando M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bansal, Vinod</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rosas, Sylvia E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nigwekar, Sagar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yee, Jerry</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kramer, Holly</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Saunders</subfield><subfield code="t">The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested</subfield><subfield code="d">2013</subfield><subfield code="d">AJKD : official journal of the National Kidney Foundation</subfield><subfield code="g">Philadelphia, Pa</subfield><subfield code="w">(DE-627)ELV011405082</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:70</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:737-751</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1053/j.ajkd.2017.07.019</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">52.56</subfield><subfield code="j">Regenerative Energieformen</subfield><subfield code="j">alternative Energieformen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">70</subfield><subfield code="j">2017</subfield><subfield code="e">6</subfield><subfield code="h">737-751</subfield><subfield code="g">15</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
author	Isakova, Tamara
spellingShingle	Isakova, Tamara ddc 610 ddc 530 bkl 52.56 Elsevier dialysis Elsevier calcium Elsevier renal osteodystrophy Elsevier clinical practice guideline Elsevier phosphate Elsevier parathyroid hormone (PTH) Elsevier Chronic kidney disease–mineral and bone disorder (CKD-MBD) Elsevier nephrology best practices Elsevier phosphate binders Elsevier mineral metabolism Elsevier end-stage renal disease (ESRD) Elsevier bone mineral density (BMD) Elsevier evidence-based medicine KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
authorStr	Isakova, Tamara
ppnlink_with_tag_str_mv	@@773@@(DE-627)ELV011405082
format	electronic Article
dewey-ones	610 - Medicine & health 530 - Physics
delete_txt_mv	keep
author_role	aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
topic_title	610 610 DNB 610 VZ 530 VZ 52.56 bkl KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) dialysis Elsevier calcium Elsevier renal osteodystrophy Elsevier clinical practice guideline Elsevier phosphate Elsevier parathyroid hormone (PTH) Elsevier Chronic kidney disease–mineral and bone disorder (CKD-MBD) Elsevier nephrology best practices Elsevier phosphate binders Elsevier mineral metabolism Elsevier end-stage renal disease (ESRD) Elsevier bone mineral density (BMD) Elsevier evidence-based medicine Elsevier
topic	ddc 610 ddc 530 bkl 52.56 Elsevier dialysis Elsevier calcium Elsevier renal osteodystrophy Elsevier clinical practice guideline Elsevier phosphate Elsevier parathyroid hormone (PTH) Elsevier Chronic kidney disease–mineral and bone disorder (CKD-MBD) Elsevier nephrology best practices Elsevier phosphate binders Elsevier mineral metabolism Elsevier end-stage renal disease (ESRD) Elsevier bone mineral density (BMD) Elsevier evidence-based medicine
topic_unstemmed	ddc 610 ddc 530 bkl 52.56 Elsevier dialysis Elsevier calcium Elsevier renal osteodystrophy Elsevier clinical practice guideline Elsevier phosphate Elsevier parathyroid hormone (PTH) Elsevier Chronic kidney disease–mineral and bone disorder (CKD-MBD) Elsevier nephrology best practices Elsevier phosphate binders Elsevier mineral metabolism Elsevier end-stage renal disease (ESRD) Elsevier bone mineral density (BMD) Elsevier evidence-based medicine
topic_browse	ddc 610 ddc 530 bkl 52.56 Elsevier dialysis Elsevier calcium Elsevier renal osteodystrophy Elsevier clinical practice guideline Elsevier phosphate Elsevier parathyroid hormone (PTH) Elsevier Chronic kidney disease–mineral and bone disorder (CKD-MBD) Elsevier nephrology best practices Elsevier phosphate binders Elsevier mineral metabolism Elsevier end-stage renal disease (ESRD) Elsevier bone mineral density (BMD) Elsevier evidence-based medicine
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	zu
author2_variant	t l n tl tln m d md s y sy d e w de dew o m g om omg v b vb s e r se ser s n sn j y jy h k hk
hierarchy_parent_title	The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested
hierarchy_parent_id	ELV011405082
dewey-tens	610 - Medicine & health 530 - Physics
hierarchy_top_title	The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)ELV011405082
title	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
ctrlnum	(DE-627)ELV041125940 (ELSEVIER)S0272-6386(17)30898-3
title_full	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
author_sort	Isakova, Tamara
journal	The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested
journalStr	The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology 500 - Science
recordtype	marc
publishDateSort	2017
contenttype_str_mv	zzz
container_start_page	737
author_browse	Isakova, Tamara
container_volume	70
physical	15
class	610 610 DNB 610 VZ 530 VZ 52.56 bkl
format_se	Elektronische Aufsätze
author-letter	Isakova, Tamara
doi_str_mv	10.1053/j.ajkd.2017.07.019
dewey-full	610 530
title_sort	kdoqi us commentary on the 2017 kdigo clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (ckd-mbd)
title_auth	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
abstract	Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment.
abstractGer	Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment.
abstract_unstemmed	Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment.
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40
container_issue	6
title_short	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
url	https://doi.org/10.1053/j.ajkd.2017.07.019
remote_bool	true
author2	Nickolas, Thomas L. Denburg, Michelle Yarlagadda, Sri Weiner, Daniel E. Gutiérrez, Orlando M. Bansal, Vinod Rosas, Sylvia E. Nigwekar, Sagar Yee, Jerry Kramer, Holly
author2Str	Nickolas, Thomas L. Denburg, Michelle Yarlagadda, Sri Weiner, Daniel E. Gutiérrez, Orlando M. Bansal, Vinod Rosas, Sylvia E. Nigwekar, Sagar Yee, Jerry Kramer, Holly
ppnlink	ELV011405082
mediatype_str_mv	z
isOA_txt	false
hochschulschrift_bool	false
author2_role	oth oth oth oth oth oth oth oth oth oth
doi_str	10.1053/j.ajkd.2017.07.019
up_date	2024-07-06T19:17:48.665Z
_version_	1803858444199919616
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041125940</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625233754.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180725s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1053/j.ajkd.2017.07.019</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000043A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041125940</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0272-6386(17)30898-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">52.56</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Isakova, Tamara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference, and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations. The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding CKD-MBD and its diagnosis, prevention, and treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">dialysis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">calcium</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">renal osteodystrophy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">clinical practice guideline</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">phosphate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">parathyroid hormone (PTH)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chronic kidney disease–mineral and bone disorder (CKD-MBD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">nephrology best practices</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">phosphate binders</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mineral metabolism</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">end-stage renal disease (ESRD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">bone mineral density (BMD)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">evidence-based medicine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nickolas, Thomas L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Denburg, Michelle</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yarlagadda, Sri</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiner, Daniel E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gutiérrez, Orlando M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bansal, Vinod</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rosas, Sylvia E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nigwekar, Sagar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yee, Jerry</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kramer, Holly</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Saunders</subfield><subfield code="t">The Audio Recorded Cognitive Screen: Outpatient reports on the experience of being tested</subfield><subfield code="d">2013</subfield><subfield code="d">AJKD : official journal of the National Kidney Foundation</subfield><subfield code="g">Philadelphia, Pa</subfield><subfield code="w">(DE-627)ELV011405082</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:70</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:737-751</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1053/j.ajkd.2017.07.019</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">52.56</subfield><subfield code="j">Regenerative Energieformen</subfield><subfield code="j">alternative Energieformen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">70</subfield><subfield code="j">2017</subfield><subfield code="e">6</subfield><subfield code="h">737-751</subfield><subfield code="g">15</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
score	7.400174

Nicht das Richtige dabei?

Schreiben Sie uns!

KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?